NCT05375643 SURGE: Supporting UnderRepresented Minorities in Genomics-based Cancer Trial Enrollment (Intervention)
| NCT ID | NCT05375643 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Nadine McCleary, MD, MPH |
| Condition | Gastrointestinal Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 210 participants |
| Start Date | 2023-04-03 |
| Primary Completion | 2027-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 210 participants in total. It began in 2023-04-03 with a primary completion date of 2027-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
SURGE aims to increase equity in clinical trial enrollment by addressing barriers to genomic testing, which is increasingly needed to assess precision clinical trial eligibility and access standard precision therapies. The study is an interventional pilot meant primarily to assess the feasibility of the intervention. The intervention is comprised of a patient navigator, text message questionnaire, and informational video.
Eligibility Criteria
Inclusion Criteria: * Adult (age 18 years or older) * Black, Latinx, OR older adult (age 70 years or older) * Scheduled for a new patient consultation * Suspected or confirmed advanced malignancy (requiring active treatment) * Gastrointestinal, hematologic, or thoracic cancer * DFCI patient at Longwood/Chestnut Hill, DFCI satellite at St. Elizabeth's Medical Center, or DFCI satellite at Merrimack Valley Exclusion Criteria: * Malignancy or former malignancy that requires only surveillance * Not continuing care at a participating DFCI site * Speaks a language other than English or Spanish * Unable to provide consent
Contact & Investigator
Nadine J McCleary, MD MPH
PRINCIPAL INVESTIGATOR
Dana-Farber Cancer Institute
Frequently Asked Questions
Who can join the NCT05375643 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Gastrointestinal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05375643 currently recruiting?
Yes, NCT05375643 is actively recruiting participants. Contact the research team at nj_mccleary@dfci.harvard.edu for enrollment information.
Where is the NCT05375643 trial being conducted?
This trial is being conducted at Boston, United States, Brighton, United States, Methuen, United States.
Who is sponsoring the NCT05375643 clinical trial?
NCT05375643 is sponsored by Nadine McCleary, MD, MPH. The principal investigator is Nadine J McCleary, MD MPH at Dana-Farber Cancer Institute. The trial plans to enroll 210 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.